Profile of adalimumab and its potential in the treatment of uveitis - Test2 - elhamkhani - TriplyDB

Profile of adalimumab and its potential in the treatment of uveitis

Profile of adalimumab and its potential in the treatment of uveitis

http://www.wikidata.org/entity/Q28077781

about

Effect of Adalimumab on Peripheral Blood Mononuclear Cells in Non-Infectious Uveitis.An Update on Treatment of Pediatric Chronic Non-Infectious Uveitis.Infliximab relieves blood retinal barrier breakdown through the p38 MAPK pathway in a diabetic rat model.Ocular delivery of proteins and peptides: challenges and novel formulation approaches.

P2860

Q41986970-8B8B8279-71BA-4F6C-A2E4-B7755ED85A2A Q41994612-037BED84-07C1-463F-98BE-03B5FA6B8D81 Q47104993-911D143E-AAB4-4F80-8381-D71854E9C8C9 Q47729137-0C57EBDD-243D-49DE-BE8A-F938497D3515

P2860

Profile of adalimumab and its potential in the treatment of uveitis

http://www.wikidata.org/entity/Q28077781

description

2016 nî lūn-bûn

@nan

2016 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած

@hyw

2016 թվականի սեպտեմբերին հրատարակված գիտական հոդված

@hy

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

name

Profile of adalimumab and its potential in the treatment of uveitis

@ast

Profile of adalimumab and its potential in the treatment of uveitis

@en

Profile of adalimumab and its potential in the treatment of uveitis

@nl

type

label

Profile of adalimumab and its potential in the treatment of uveitis

@ast

Profile of adalimumab and its potential in the treatment of uveitis

@en

Profile of adalimumab and its potential in the treatment of uveitis

@nl

prefLabel

Profile of adalimumab and its potential in the treatment of uveitis

@ast

Profile of adalimumab and its potential in the treatment of uveitis

@en

Profile of adalimumab and its potential in the treatment of uveitis

@nl

P1433

Q28077781-AF16C8FC-156C-42C7-9092-DEAA315EDE9C

P1476

Q28077781-2CE77573-629B-4FCE-9A53-8E6AECF028DE

P2093

Q28077781-B2B01361-01B1-47B8-B6D8-10031FF60923

P275

Q28077781-387E70B8-827E-475F-91E4-436A7C974533

P2860

Q28077781-0642E2C5-1F02-4C0A-8F38-C6F14CAC701A

Q28077781-0971D1F1-B1D0-41C7-A386-71FF1F0066AA

Q28077781-0A4AB782-2CE1-4ADA-9DFF-FBF3CCA7200C

Q28077781-1ABB311B-22E5-4F03-97ED-FD42B2F4575E

Q28077781-218AE57E-8093-4D78-B20C-EDAD5A4516C7

Q28077781-272CB1C2-5345-4CE3-9E9B-F1F678653F31

Q28077781-3A3B6F1F-6545-447D-B76C-CF4624DA5CD4

Q28077781-3C0ECD6C-9605-44DD-A9FC-945A3EB7A390

Q28077781-3C322ACD-5741-4978-8ECA-0236B398ACBC

Q28077781-46D6A47B-DBBA-4430-85A8-73C40CC3B852

P304

Q28077781-F303338D-406F-4D56-9821-FC2637D74937

P31

Q28077781-88439A41-F8F0-46BD-BBDD-2F7803995C09

Q28077781-BFF67FF9-1BA4-48C3-B416-6BDE3EB9A455

P3181

Q28077781-391A5348-7659-4BD1-A05E-140DD7E67626

P356

Q28077781-12310415-C877-47D1-B95A-EEAAB297C34F

P407

Q28077781-07E5C8DC-E155-4376-B5ED-4DD73858C6F2

P478

Q28077781-AC7741E7-E095-4219-817A-B01D4926295E

P50

Q28077781-8F5E2EAA-4081-4081-AC08-9B321D80EE78

P5008

Q28077781-81153913-1553-48CE-8B05-6835A3F2EB7F

P577

Q28077781-6AF156D6-C659-4ECF-B2C1-D2DE6E23FDF1

P698

Q28077781-B2897DF4-3E88-4DF3-BEE8-846A4D156756

P921

Q28077781-0AB2B6B9-E4DA-4D8C-B86E-0E6376A75637

Q28077781-0F382509-3114-4463-9C80-B83FFA9B623D

Q28077781-15F114BB-8F1F-494B-A665-8FDA133FDD02

Q28077781-425EB17F-6CA4-4111-B5C7-F63E78FB9BD5

Q28077781-48B04691-ECA1-4C6E-AF3F-B2CCFC607245

Q28077781-7BBC921A-646D-42B8-88F9-F9608CE3802C

Q28077781-C2D11ABB-025E-424F-B7E9-0010408400C5

Q28077781-D0207843-0C80-41E8-8E9C-A5EC772A5699

Q28077781-D7698C59-3AAD-4166-ADC5-E939D981C72C

Q28077781-F5A27185-32F1-444E-8CAD-937CB68AA078

P932

Q28077781-F4F08125-DA8B-4E2A-B9CC-F3F892F883B6

P3181

P356

P1433

Drug Design, Development and Therapy

P1476

Profile of adalimumab and its potential in the treatment of uveitis

@en

P2093

C. Egla Rabinovich

http://www.w3.org/2001/XMLSchema#string

P275

Creative Commons Attribution-NonCommercial

P2860

Standardization of uveitis nomenclature for reporting clinical data. Results of the First International Workshop

The Future Is Now: Biologics for Non-Infectious Pediatric Anterior Uveitis

Safety and efficacy of infliximab and adalimumab for refractory uveitis in juvenile idiopathic arthritis: 1-year followup data from the Italian Registry.

Anti-TNF agents for Behçet's disease: analysis of published data on 369 patients.

Immune mechanisms of uveitis: insights into disease pathogenesis and treatment.

Ocular sarcoidosis.

Sarcoidosis and uveitis.

Expert panel recommendations for the use of anti-tumor necrosis factor biologic agents in patients with ocular inflammatory disorders.

Current evidence of anti-tumor necrosis factor α treatment efficacy in childhood chronic uveitis: a systematic review and meta-analysis approach of individual drugs.

Adalimumab in the therapy of uveitis in childhood

P304

2997-3003

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

3463144

http://www.w3.org/2001/XMLSchema#string

P356

10.2147/DDDT.S94188

http://www.w3.org/2001/XMLSchema#string

P407

P478

10

http://www.w3.org/2001/XMLSchema#string

P50

Stephen Balevic

P5008

P577

2016-09-19T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27698552

http://www.w3.org/2001/XMLSchema#string

P921

heterocyclic compound

Tumor necrosis factor

monoclonal antibody

juvenile rheumatoid arthritis

P932

5034916

http://www.w3.org/2001/XMLSchema#string